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SHORT COMMUNICATION
The cytotoxic activity of Taxol in primary cultures of tumour cells from
patients is partly mediated by Cremophor EL
P Nygren', K Csoka2, B Jonsson2, H Fridborg2, J Bergh', H Hagberg', B Glimelius', 0 Brodin',
B Tholander3, A Kreuger', G Lonnerholm4, A Jakobsson4, L Olsen5, J Kristensen6 and
R Larsson2
'Department ofOncology; 2Division ofClinical Pharmacology and Departments of3Gynecologic Oncology, 'Pediatrics, 'Pediatric
Surger) and 'Internal Medicine, University Hospital, Uppsala University, S-751 85 Uppsala, Sweden.
Sary In patient tumour samples the activity in vitro of Taxol corresponded fairly well to the known
clinical activity and Taxol showed low cross-resistance to standard cytotoxic drugs. However, tbe Taxol
solvent Cremophor EL-ethanol was considerably active alone, wbereas paclitaxel formulated in ethanol was
less active. Taxol thus seems to contain two components active against patient tumour cells in vitro.
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Phase II studies have indicated activity of Taxol in several
solid tumour types (Rowinsky et al., 1992). The formulation
of paclitaxel in 50% (v/v) Cremophor EL (CEL) and 50%
ethanol (Taxol) potentially induces another type of anti-
tumour activity. CEL has thus been found to reverse P-
glycoprotein-mediated multidrug resistance (Schuurhuis et
al., 1990; Fjallskog et al., 1994) and CEL may have a
cytotoxic effect (Fjallskog et al., 1994). Interestingly, concent-
rations of the solvent active in vitro may be reached in
patients treated with Taxol (Webster et al., 1993).
The present study was undertaken to investigate in vitro
the activity of standard cytotoxic drugs in comparison with
various formulations of paclitaxel and its solvent in tumour
samples from patients and in a cell line, using the fluoro-
metric microculture cytotoxicity assay (FMCA; Larsson et
al., 1992; Nygren et al., 1992, 1994a, b).
Materals and
Tunour sanples and cellpreparatin
The activity of Taxol and six standard cytotoxic drugs was
tested in a total of 492 tumour samples obtained from
patients with various tumour types as detailed in Table I.
Because of the limited number of cells, not every sample was
tested for every drug. The total numbers of samples included
for each diagnosis and drug are indicated in Table I. The
samples were not separated for prior chemotherapy. Tissue
from primary tumours or metastases was used and the samp-
ling was mostly performed during routine treatment or diag-
nostic work-up. Tumour cells were prepared by collagenase
digestion or Ficoll-Isopaque density gradient centrifugation
depending on the type of sample as described previously
(Nygren et al., 1994a).
The percentage of tumour cells was judged by light micro-
scopic examination of stained cytocentrifuge preparations.
Culture medium RPMI-1640 (HyClone, Cramlington, UK)
supplemented with 10% fetal calf serum, glutamine, strepto-
mycin and penicillin was used throughout (Nygren et al.,
1994a). Some cell preparations were cryopreserved in liquid
nitrogen before analysis. This does not alter the cytotoxic
drug sensitivity (Nygren et al., 1992, and unpublished
data).
The P-glycoprotein-deficient myeloma cell line RPMI 8226
was kept under standard culture conditions; its characteristics
with respect to cytotoxic drug sensitivity assessed by the
FMCA have been described previously (Jonsson et al.,
1992).
Cytotoxic drugs
For CEL-ethanol-formulated paclitaxel, the clinical formula-
tion (Taxol, Bristol-Myers Squibb, Bromma, Sweden) con-
taining 6mgmln' paclitaxel in 50% CEL and 50% ethanol
(v/v) was used. It was further diluted in sterile water and was
tested at the concentration range 0.2-25 ig ml-' for assess-
ment of the dose-response pattern and at 1 or 5 #Lg m1n l for
comparison between diagnoses and with other drugs. Corre-
sponding amounts (Figure 1) of CEL (Sigma)/ethanol and
paclitaxel (Sigma) dissolved in ethanol alone were used in
control experiments to check for the effect of the solvents.
The six standard cytotoxic drugs tested are detailed in Table
I. The origin and solvents used for these drugs were as
described previously (Larsson et al., 1992; Nygren et al.,
1994a). The cytotoxic drug concentrations used for activity
evaluation, estabished from dose-response curve in haema-
tological malignancies as described by Larsson et al. (1992),
are indicated in Table I.
FMCA procedure
The principal steps of the assay have been described
previously (Larsson et al., 1992). Briefly, on day 1 180;gl of
the tumour cell preparation (2.5-5 x I05cells per ml of
medium for leukaemia/lymphoma samples and 5-10 x 10I
cells ml- for solid tumours/RPMI 8226 cell line) was added
to each well of the microtitre plates prepared in advance with
the cytotoxic drugs (Larsson et al., 1992). The plates were
then incubated at standard culture conditions for 72 h fol-
lowed by washing in buffer and addition of buffer containing
1O ig ml1- fluorescein diacetate (FDA). After incubation for
30-60 min at 37TC the fluorescence from each well was
measured in a Fluoroscan 2 (Labsystems OY, Helsinki, Fin-
land). Quality criteria for a successful assay were as defined
previously (Nygren et al., 1994a). Only data for successfully
analysed samples are included.
Quantification ofFMCA results
The results are presented either as survival index (SI) or in
vitro response rate at the drug concentrations defined above
and detailed in Table I. SI was defined as the fluorescence of
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November 1994experimental cultures in per cent of controls, with blank
values subtracted. The in vitro response rate for a given drug
was defined as the percentage of samples showing SI values
below the median, calculated from all samples included in the
study of that drug. Cross-resistance between drugs is expressed
as Pearson's coefficient of correlation (Colton, 1974).
Results
Dose-response relationships for Taxol in haematological and
solid tumour samples indicated that the greatest response
variation was observed at 5 jg ml-' with mean SI values of
32% and 56% respectively (Figure la and b). This concentra-
tion was therefore used for testing samples with low cell
yield.
The activity in vitro of Taxol and the standard drugs is
shown in Table I. The ALL, NHL and, to a lesser extent, the
AML samples showed mostly high response rates to the
standard drugs. Carcinomas of the ovary and breast as well
as paediatric solid tumours, soft-tissue sarcomas and lung
carcinomas showed very variable, but on average inter-
mediate, sensitivity. Kidney carcinomas and the assorted
group responded poorly to the standard drugs.
Taxol, on the other hand, was most active in paediatric
solid tumours, NHL, soft-tissue sarcomas, ALL and car-
cinomas of the breast, and least active in AML. This pattern
of activity was also obtained when tested at 1 g ml1' (not
shown).
The coefficients of correlation between the standard drugs
varied between 0.36 and 0.76, with most values above 0.50
(Table II). In contrast, the coefficients of correlation between
Taxol and the standard drugs varied between 0.10 and 0.26,
with the exception being Vpl6, for which it was 0.47.
The dose-response relationships for Taxol and the corre-
sponding amounts of CEL-ethanol alone were similar,
whereas those for paclitaxel-ethanol were less steep (Figure
la and b). When including some more samples investigated
at 1 and 5 ;Lg ml- Taxol or the corresponding amounts of
the solvent, it was found that 42-100% of the decreases in
SI values were due to CEL-ethanol alone, with the most
pronounced effect in the solid tumours (not shown). Ethanol
alone was without cytotoxic effect, whereas CEL alone was
as effective as the CEL-ethanol mixture (not shown). In the
RPMI 8226 cell line, paclitaxel was considerably more active
than in the patient samples irrespective of formulation
(Figure lc). In the cell line, CEL-ethanol alone was rela-
tively less active.
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Fue I Effect on survival index of increasing concentrations of
paclitaxel formulated in ethanol (0), CEL-ethanol (Taxol; 0)
or CEL-ethanol alone (A) in haematological (a; n = 4), and
solid (b; n = 7) samples and in the RPMI 8226 myeloma ce line
(c; n = 4) after 72 h incubation. The total solvent (CEL +
ethanol) concentrations (v/v) in the Taxol and CEL-ethanol
preparations were 0%, 0.0034%, 0.017%, 0.084% and 0.42%
respectively for the indicated paclitaxel concentrations. Paclitaxel
formulated in ethanol contained the corresponding concentra-
tions of ethanol. The results are presented as mean values ± s.e.
of triplicate wells for the indicated number of experiments.
Table I Response rates for the included samples for the six standard drugs and Taxol at the indicated concentrations
Cytotoxic drug
Vcr 4HC Cisp Vpl6 Mitox Dox Taxol
Diagnosis 0.5jigml' I 2p.gmI- 2jgml-I' 5 Agml- 0.5jAg ml- t 0.5jigmi- I 5jgml-t
ALL 56/69 (81) 42/48 (88) 42/57 (72) 67/88 (76) 73/87 (84) 71/91 (78) 21/34 (62)
AML 47/103 (46) 33/64 (52) 16/40 (40) 71/139 (51) 92/134 (69) 83/136 (61) 8/38 (21)
NHL 32/37 (86) 49/55 (89) 32/59 (54) 45/79 (57) 51/64 (80) 61/80 (76) 17/23 (74)
Ovarian carcinoma 13/33 (39) 7/37 (19) 18/37 (49) 8/37 (22) 1/36 (3) 7/37 (19) 12/28 (43)
Soft-tissue sarcoma 6/23 (26) 10/24 (42) 11/23 (48) 13/24 (54) 1/23 (4) 5/22 (23) 10/16 (62)
Paediatnrc solid tumours 7/19 (37) 10/20 (50) 10/21 (48) 11/21 (52) 3/19 (16) 4/19 (21) 12/15 (80)
Breast carcinoma 8/19 (42) 10/30 (33) 11/26 (42) 8/27 (30) 3/25 (12) 5/33 (15) 16/26 (62)
NSCLC 318 (38) 119 (11) 6/9 (67) 3/8 (38) 1/8 (12) 2/10 (20) 2/7 (29)
SCLC 2/9 (22) 6/10 (60) 61/10 (60) 4/10 (40) 1/10 (10) 0/10 (0) 2/6 (33)
Kidney carcinoma 1 20 (5) 1/22 (5) 1/22 (5) 5/22 (23) 0/22 (0) 1/22 (5) 2/9 (22)
Assorted solid tumours 3/15 (20) 6/25 (24) 8/25 (32) 7/23 (30) 0/19 (0) 2/24 (8) 7/24 (29)
The table shows the number of samples, ofall samples investigated for each diagnosis and drug, with a survival index below the
median for each drug. The response rates so defined are also indicated in per cent within parentheses. Drug abbreviations: Vcr,
vincristine; 4HC, 4-hydroperoxycyclophosphamide; Cisp, cisplatin; Vpl6, etoposide; Mitox, mitoxantrone; Dox, doxorubicin. The
soft-tissue sarcoma group includes samples from adult patients only. Paediatric solid tumours included soft-tissue sarcoma (1),
Ewing's sarcoma (6), Wilms' tumour (6), neuroblastoma (7) and rhabdomyosarcoma (1). The assortedsolid tumour group included
adenocarcinomas of the parotid (3), thyroid (1), adrenal cortex (2), oesophagus (2), prostate (1), parathyroid (1) and medullary
thyroid (2), melanoma (3), glioma (1), paraganglioma (1), carcinoid (5), squamous epithelial carcinoma (2) and hepatocellular
carcinoma (1). Diagnosis abbreviations: ALL, acute lymphoblastic leukaemia; AML, acute myeloblastic leukaemia; NHL,
non-Hodgkin's lymphoma; NSCLC, non-small-ell lung cancer; SCLC, small-cell lung cancer.PN)-en eta
Table H Cross-resistance pattern for all invesgated samples
Ver 4HC Cisp Vp)6 Mitox Dox
4HC 0.53
Cisp 0.54 0.56
Vpl6 0.41 0.52 0.36
Mitox 0.61 0.76 0.52 0.56
Dox 0.57 0.64 0.55 0.54 0.76
Taxol 0.15 0.26 0.10 0.47 0.18 0.26
The table shows the coefficients of correlation between SI values
obtained for the indcated pairs ofdrugs for all samples indicated in
Table I. Each correlation is based on 139-486 data points.
Discomso
The FMCA seems to detect disease-specific activity of stan-
dard drugs in haematological (Larsson et al., 1992; Nygren et
al., 1992, 1994b) and solid tumours (Nygren et al., 1994a).
The present standard drug data add to the impron that
the FMCA may be a valid assay. The FMCA may thus
provide important information on the propertes ofinvestiga-
tional drugs before those data can be extracted from cinical
trials.
Taxol has been found to be one of the most active drugs in
patients with previously treated ovarian (Einzig et al., 1992;
Rowinskly et al., 1992) and previously treated (Holmes et al.,
1991; Nabholtz et al., 1993) or untreated (Seidman et al.,
1992) breast carcinoma and with retained activity also in
anthracycline-resistant breast carcinoma (Holmes et al., 1991;
Seidman et al., 1993). In untreated advanced NSCLC, the
response rate seems to be low, slightly above 20% (Chang et
al., 1992; Murphy et al., 1993) and no responses were
observed in 18 patients with advanced kidney carcinoma
(Einzig et al., 1991).
The findings in vitro of a high activity of Taxol relative to
standard drugs in carcinomas of the ovary and breast and
the low activity in NSCLC and kidney carcinomas are thus
reminiscent of the clinical data obtained so far and may
indicate the vaLidity of the FMCA also for testng Taxol.
Much of the effect of Taxol in the patient tumour samples
could be attributed to the solvent CEL, especially in the solid
tumour samples. The biological activity of the pacitaxel-
ethanol preparation was confirmed by a pronounced cyto-
toxic effect in the RPMI 8226 myeloma cell line, whereas in
this system the solvents were relatively less cytotoxic. The
latter pattern of activity of the various preparations has also
been observed in breast cacer cell lines (Fjillskog et al.,
1994).
Could it be that the effects of Taxol and the solvent are
not accurately measured in the FMCA? The quantitative
effects of the paclitaxel and solvent preparations were
confirmed in control experiments using the trypan blue ex-
clusion test or a modification (Kristensen et al., 1992) of the
well-established disc assay (Weisenthal et al., 1983) as end
points (not shown). Furthermore, in control experiments, the
redox indicator Alamar Blue (Alamar, Sacramento, CA,
USA), which measures the metabolic activity of the cells, was
used instead of FDA as viability indicator (Pag* et al., 1993)
in the final step of the FMCA with essentially identical
results (not shown).
It was recently found that a CEL concentration in plasma
of >0.1% (v/v), which is close to the 0.042% at 5 tgml-'
Taxol in vitro, is usually reached at the end of a 3 h Taxol
infusion in patients (Webster et al., 1993). It is not known if
the tumour cells will really be exposed to these levels of CEL
in vivo and if an anti-tumour effect could thus be obtained.
This could perhaps only be elucidated by actually treating
patients with CEL alone.
CEL contains castor oiL which is a mixture of fatty acids
(Budavari et al., 1989) which may be more toxic to tumour
than to normal cells (Burton, 1991) and to multidrug-
resistant cells than to parental tumour cell lines (Weber et al.,
1994). The selectivity may be due to the apparent differences
in the membrane compositions (Shinitzky and Inbar, 1974;
Arsenault et al., 1988; Wseman, 1994). We found a decrease
in cell survival after only 3h of incubation in Taxol or
CEL-ethanol (not shown). This is reminiscent of the rapid
cytotoxic effect of fatty acids (Burton, 1991), indicating
related mechnis of action. The possibility of a unique
cytotoxic effect ofCEL in Taxol would also explain the poor
cross-resiance to the standard drugs.
The differences in activity ofTaxol and its solvent between
cell lines and the patient samples could be because cell ines
under the present conditions proliferate, whereas the tumour
cells from clinical samples in most cases do not. During its
development Taxol was tested against proliferating cell lines
in vitro or as xenografts in vivo prior to introduction of the
drug in clnical studies (Rowinsky et al., 1992). This might
explain why a substantial effect of the solvent against patient
tumour cells was never discovered.
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